Solara Active Q1 FY26: API Titanic Finally Surfacing or Just Another Bubble Bath?
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Solara Active Pharma just posted a profit after spending two years in “how low can we go” mode. From –₹567 Cr in FY24 to ₹10.5 Cr this quarter, they’re back in black—barely. The stock popped 6%, probably because no one died this time.
Q1 FY26 PAT: ₹10.5 Cr
Revenue: ₹319 Cr (+15% QoQ)
OPM: 18%
P/E: A jaw-dropping 5,708x (yes, even your calculator rolled its eyes)
2. Introduction with Hook
Picture a pharmaceutical Titanic that hit every iceberg from Sequent to Strides and still asked for dessert. Now, imagine that same ship found a lifeboat, patched up its hole, and waved at shareholders saying, “We good now?” That’s Solara for you.
FY24 Loss: ₹567 Cr
FY25: Tiny ₹1 Cr PAT
Q1 FY26: ₹10.5 Cr profit — applause, confusion, and mild disbelief all around
3. Business Model (WTF Do They Even Do?)
Solara is in the pure-play API game, but with more drama than a Zee TV serial. They manufacture and export bulk drugs, serving 73+ countries and obsessing over 10 molecules that make up 84% of revenue.
Their APIs treat everything from parasites to paranoia (anthelmintics to anti-infectives), and they also do CRAMS work—because why not throw in more acronyms?
Think of it as B2B chemistry… just don’t ask where the “P” in profitability went the last few years.
4. Financials Overview
We finally got a quarter where the patient didn’t flatline.
